ASTROCYTOMA, IDH-MUTANT, GRADE 2
Clinical trials for ASTROCYTOMA, IDH-MUTANT, GRADE 2 explained in plain language.
Never miss a new study
Get alerted when new ASTROCYTOMA, IDH-MUTANT, GRADE 2 trials appear
Sign up with your email to follow new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for brain tumor patients: targeted drug shows promise in phase 3 trial
Disease control Recruiting nowThis study tests a drug called safusidenib in people with a type of brain tumor (glioma) that has a specific gene mutation (IDH1). The trial has three parts: one for recurrent tumors, one for high-risk tumors after standard treatment, and one for a specific tumor type after surge…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 2
Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
Experimental drug triapine paired with radiation targets recurrent brain cancers
Disease control Recruiting nowThis early-phase trial tests the safety and best dose of the drug triapine when given together with radiation therapy for people whose glioblastoma or astrocytoma has come back. Triapine works by blocking enzymes that cancer cells need to grow, while radiation kills cancer cells …
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 2
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC